189 related articles for article (PubMed ID: 20349059)
1. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
[TBL] [Abstract][Full Text] [Related]
2. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
3. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.
Tsushima F; Yao S; Shin T; Flies A; Flies S; Xu H; Tamada K; Pardoll DM; Chen L
Blood; 2007 Jul; 110(1):180-5. PubMed ID: 17289811
[TBL] [Abstract][Full Text] [Related]
4. B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis.
Hamel KM; Cao Y; Wang Y; Rodeghero R; Kobezda T; Chen L; Finnegan A
Eur J Immunol; 2010 Nov; 40(11):3117-27. PubMed ID: 21061440
[TBL] [Abstract][Full Text] [Related]
5. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.
Lin PY; Sun L; Thibodeaux SR; Ludwig SM; Vadlamudi RK; Hurez VJ; Bahar R; Kious MJ; Livi CB; Wall SR; Chen L; Zhang B; Shin T; Curiel TJ
J Immunol; 2010 Sep; 185(5):2747-53. PubMed ID: 20686128
[TBL] [Abstract][Full Text] [Related]
6. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
Martin-Orozco N; Wang YH; Yagita H; Dong C
J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
Keir ME; Latchman YE; Freeman GJ; Sharpe AH
J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
[TBL] [Abstract][Full Text] [Related]
8. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
10. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
[TBL] [Abstract][Full Text] [Related]
11. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
13. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
14. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft.
Morita M; Fujino M; Jiang G; Kitazawa Y; Xie L; Azuma M; Yagita H; Nagao S; Sugioka A; Kurosawa Y; Takahara S; Fung J; Qian S; Lu L; Li XK
Am J Transplant; 2010 Jan; 10(1):40-6. PubMed ID: 19889124
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
16. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.
Dias P; Giannoni F; Lee LN; Han D; Yoon S; Yagita H; Azuma M; Sarawar SR
J Virol; 2010 Aug; 84(16):8241-9. PubMed ID: 20534854
[TBL] [Abstract][Full Text] [Related]
17. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
Zhang L; Gajewski TF; Kline J
Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
[TBL] [Abstract][Full Text] [Related]
19. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
20. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
